{"contentid": 488722, "importid": NaN, "name": "ASCO 2021: Novartis readies varied portfolio", "introduction": "Swiss pharma giant Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 ASCO Annual Meeting.", "content": "<p>Swiss pharma giant Novartis (NOVN: VX) will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 ASCO Annual Meeting.</p>\n<p>Susanne Schaffert, president, Novartis Oncology, said: &ldquo;Our bold ambition is to extend and improve the lives of those living with cancer and serious blood disorders, and ultimately find cures.</p>\n<p>&ldquo;These exciting data from across our four therapeutic platforms illustrate how we are uniquely positioned to deliver transformative innovations that may bring renewed hope for patients.&rdquo;</p>\n<p>Key ASCO data will include efficacy and safety results from the Phase III VISION study of the investigational targeted radioligand therapy 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.</p>\n<p>There will also be Kisqali (ribociclib) overall survival (OS) analysis from MONALEESA-3, a Phase III study of postmenopausal patients with HR+/HER2&minus; advanced breast cancer treated with fulvestrant and ribociclib.</p>\n<p>Further breast cancer data will be presented on Piqray (alpelisib), while there will be Kymriah (tisagenlecleucel) updated efficacy and safety results from the Phase II ELARA trial in relapsed or refractory follicular lymphoma, along with findings on tislelizumab in advanced/unresectable metastatic esophageal squamous cell carcinoma and a solid tumors indication.</p>", "date": "2021-05-25 10:18:00", "meta_title": NaN, "meta_keywords": "Novartis, ASCO, data, portfolio, targeted, investigational, radioligand, cell, cancer, varied, readies, giant, pharma, Swiss, Annual, Meeting, upcoming", "meta_description": "Swiss pharma giant Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-24 22:21:52", "updated": "2021-05-25 10:18:51", "access": NaN, "url": "https://www.thepharmaletter.com/article/asco-2021-novartis-readies-varied-portfolio", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "novartis_logo_big.jpg", "image2id": "novartis_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "ASCO, Conferences, Drug Trial, Research", "geography_tag": "Switzerland", "company_tag": "Novartis", "drug_tag": "177Lu-PSMA-617, Kisqali, Kymriah, tislelizumab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-25 10:18:00"}